Latest news and articles about pharmaceutical industry from NEX English
CVC Capital Partners is looking to gather investors to help finance its proposed acquisition of the Italian pharmaceutical company Recordati, valued at approximately <strong>€10.9 billion</strong> (around <strong>$12.7 billion</strong>). This move aims to enhance the company's competitive edge in the global pharmaceutical market.
Novo Nordisk's CEO revealed that the weight loss drug industry has only reached <strong>15%</strong> of potential customers, indicating significant untapped opportunities. This statement comes amid rising global demand for weight loss medications.
Insilico Medicine has announced a collaboration agreement with Eli Lilly worth <strong>$2.75 billion</strong> aimed at developing new drugs. This partnership comes at a time when the pharmaceutical industry is increasingly turning to modern technology for research and development.
Pharmaceutical companies in Germany and Switzerland have warned that new US tariffs on drug products pose a serious threat to production sites in Europe, raising concerns about the future of the industry.
German Pharmaceutical Association President Dorothea Brackmann has warned of potential drug shortages in Germany stemming from the ongoing conflict in Iran, highlighting the country's heavy reliance on imported raw materials from the region.
Eli Lilly's CEO, Dave Ricks, announced the company's opposition to the White House's efforts to legislate a 'most favored nation' policy for drug pricing. This comes as the U.S. administration seeks to affirm lower drug prices in the American market.
Fabros Pharmaceutical Company announced a net profit of <strong>27.44 billion Indonesian rupiah</strong> in 2025, recovering from a loss of <strong>290.63 billion rupiah</strong> the previous year. This positive turnaround is attributed to a <strong>26.34%</strong> increase in sales.
Eli Lilly, a leading American pharmaceutical company, has announced its acquisition of Synthego for <strong>$7.8 billion</strong>, marking its entry into the growing sleep disorder medication market. This strategic move aims to expand the company's portfolio and enhance its position in the pharmaceutical industry.
Biogen, a company specializing in drug development, has announced its acquisition of Apellis Pharmaceuticals for <strong>$5.6 billion</strong>. This move aims to expand Biogen's capabilities in treating kidney diseases, addressing the growing need for effective therapies.
Lilly, the American pharmaceutical giant, has announced its acquisition of a company specializing in the development of a drug for narcolepsy, in a deal valued at up to <strong>$7.8 billion</strong>. This move aims to expand the company's market presence and enhance its drug portfolio.
The Assistant Head of the Egyptian Drug Authority confirmed that the authority regularly monitors the manufacturing process, ensuring that the strategic drug stock remains stable despite industry challenges. This reflects the commitment to meet citizens' health needs.
Eli Lilly, a leading American pharmaceutical company, has announced a strategic deal worth up to <strong>$2.75 billion</strong> with Hong Kong-based Insilico Medicine to develop drugs discovered using <strong>artificial intelligence</strong>. The agreement includes an initial payment of <strong>$115 million</strong>, with potential additional earnings tied to regulatory and commercial milestones.
CVC Capital Partners plans to explore potential divestment options for the Italian pharmaceutical company Recourati following its successful acquisition for €10.9 billion. This move is part of CVC's strategy to enhance its investment portfolio.
Merck & Co. is in advanced talks to acquire Turners Pharmaceuticals, a move aimed at strengthening its portfolio of drugs and treatments. This acquisition reflects Merck's strategy to expand its presence in the global pharmaceutical market.